CTOs on the Move

Arkuda Therapeutics

www.arkudatx.com

 
Arkuda Therapeutics is a biotechnology company applying insights into lysosomal biology to drive the development of medicines to change the trajectory of neurodegenerative disease. Arkuda`s lead program ARKD-104 aims to correct progranulin deficiency and lysosomal dysfunction in patients with GRN-related frontotemporal dementia (FTD-GRN), a genetically-defined subtype of frontotemporal dementia caused by an autosomal dominant mutation in the progranulin (GRN) gene. The company is further exploring the therapeutic potential of its molecules in other neurodegenerative diseases where genetic links to dysfunction in progranulin biology have been established, including Alzheimer`s Disease and Parkinson`s Disease. Arkuda is backed by leading investors including Atlas ...
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.arkudatx.com
  • 200 Arsenal Yards Boulevard Suite 220
    Watertown, MA USA 02472
  • Phone: 617.579.1306

Executives

Name Title Contact Details
Duane Burnett
Chief Technology Officer Profile

Funding

Arkuda Therapeutics raised $44M on 11/07/2019

Similar Companies

ChemDiv

ChemDiv Inc. (Chemical Diversity) is a global chemistry-driven contract research organization focused on identifying and delivering discovery opportunities and services for life science partners, and merging industrial and academic efforts to bring new

Dyno Therapeutics

Dynotx.com provides cutting-edge sales and marketing tools for small and medium-sized businesses. Their services include web design, social media management, advertising, and SEO optimization. They aim to help businesses grow and succeed online by prov...

bioMASON

We build with carbon the same way nature does. Our biocement® materials are healthier for us and the Planet.

CovX Research

CovX Research is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Greffex

Greffex™ is a privately held, multi-national company, headquartered in Aurora, Colorado. Established in 1999, Greffex has developed a novel genetic platform for the development and production of vaccines. Our proprietary GREVAX™ Universal Platform delivers vaccines in a faster, more affordable and more efficient manner. Once a pathogen has been identified, Greffex`s team designs and produces a GREVAX™ vaccine in as little as 4 weeks. The state-of-the-art flexibility of the GREVAX™ Universal Platform makes it the ideal delivery vehicle for vaccines against a wide variety of infectious disease, including but not limited to Pandemic Influenza strains, Anthrax and Dengue Fever, as well as Malaria, Hepatitis C, Respiratory Syncytial Virus (RSV), Ebola, HPV, Plague, Tuberculosis and a host of other vaccine candidates.